On April 1, 2005 Yamanouchi and Fujisawa merged to form Astellas. Astellas Pharma Inc develops and markets pharmaceuticals which provide the promise of a healthier life to people across the world. As a global pharmaceutical company Astellas is determined to be the ‘Leading Light for Life.’ Currently we have two plants in Ireland which are based in Kerry and Dublin.
The Kerry Plant formulates an immunosuppressant called Prograf one of Astellas Pharma Incs’ most important and innovative drugs, using the latest encapsulation, ampoule filling and packaging technology which is used to prevent the rejection of transplanted organs. Worldwide distribution is from Killorglin. Protopic (tacrolimus ointment) indicated for patients suffering from moderate to severe atopic dermatitis is packaged in Killorglin and distributed to the European market. The Kerry Plant was established in Killorglin in 1990 and presently employs over 290 people.
The Dublin Plant’s main activity includes the manufacture of three bulk active pharmaceutical ingredients which are supplied to the global market, namely, Famotidine (stomach ulcer treatment), Solifenacian (urinary frequency, urinary incontinence or urgency associated with over active bladder) and Tamsulosin (prostrate gland problems). The Dublin Pant was established in Mulhuddart in 1986 and presently employs over 70 people.
Astellas is an equal opportunities employer.
Please enter your email address
Please enter a valid email address
Astellas Ireland (Dublin) a leading Japanese pharmecutical company is now recruiting for a permanent QA Specialist to join our Quality Assurance Team at our API plant in Dublin 15.